FULC Stock Crashes After Hours: What Investors Need To Know

Fulcrum Therapeutics (NASDAQ:FULC) shares are trading sharply lower in after-hours trading on Monday.

FULC shares plunged 49.69% to $3.23 in after-hours trading after the company announced it was discontinuing pociredir, its lead experimental drug for sickle cell disease, and launched a strategic review process.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare hematological disorders.

Program Discontinuation Announcement

The company said it is discontinuing development of pociredir for sickle cell disease following feedback from the Food and Drug Administration.

According to Fulcrum, the FDA raised concerns about the benefit-risk profile of pociredir after observing malignancy risks associated with Tazverik, another drug targeting the PRC2 pathway that was withdrawn from the global market earlier this year. The FDA concluded that therapies targeting the PRC2 complex may carry similar cancer-related risks, leaving no viable regulatory path forward for pociredir.

Strategic Review

Following the decision, Fulcrum announced a comprehensive review of strategic alternatives, including a potential merger, acquisition, business combination or other transactions designed to maximize shareholder value.

The company also said it will significantly reduce operating expenses and preserve capital while evaluating its options. As of March 31, 2026, Fulcrum reported $333.3 million in cash, cash equivalents and marketable securities.

Trading Analysis

Fulcrum Therapeutics currently has a market capitalization of approximately $427.79 million, with a 52-week high of $15.74 and a 52-week low of $5.88.

The stock is down 7.76% over the past 12 months.

Price Action: According to market data, FULC closed Monday’s regular trading session at $6.42. Shares later plunged 49.69% in after-hours trading to $3.23.

Benzinga Edge Stock Rankings indicate that FULC shares currently maintain negative short, medium and long-term price trends.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors